The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.
Research article published in The Malaysian journal of medical sciences : MJMS (2008)
Abstract
Our objectives were to discuss a general overview on the description and recognition of heparin-induced thrombocytopenia (HIT) and present a critical review of the traditional and most recent advances in its pharmacotherapy. Computerized searches were done on MEDLINE and Iowa Drug Information Service (IDIS) databases from June 2001 until June 2007 and from May 2005 until May 2007, respectively. Search terms used included 'heparin-induced thrombocytopenia', 'heparin-associated thrombocytopenia', therapeutics, HIT, HAT. We largely selected publications within the timeframe above, but did not exclude commonly referenced and highly regarded older publications. The commonly referenced published articles were obtained through manual searches derived from bibliographic citations and retrievals from the authors' personal files. Pertinent literatures (89 key articles) that were thought to have substantially contributed new information to the therapeutics of HIT within the last 6 years were identified, reviewed and presented. The following limits were used for the MEDLINE and IDIS searches: 'human', drug therapy', 'review', 'meta-analysis', 'clinical trial', and case reports. The therapeutics of HIT is rapidly evolving and needs to consider an evidence - based approach. It is imperative that practitioners be aware of the associated risk and be up-to-date with the current advances in the management of this fatal clinical condition.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.
Por qué esto importa para la hirudoterapia
Este artículo presenta una revisión de la literatura que aborda el reconocimiento y la farmacoterapia de la trombocitopenia inducida por heparina (TIH), resumiendo los enfoques terapéuticos tradicionales y emergentes identificados mediante búsquedas sistemáticas en bases de datos de MEDLINE e IDIS. Para el ámbito de ASH, la TIH es una complicación protrombótica del tratamiento con heparina —una afección cuyo manejo incluye anticoagulantes alternativos, algunos de los cuales (p. ej., inhibidores directos de la trombina como bivalirudina o lepirudina) comparten parentesco mecanístico con la hirudina, el arquetipo de inhibidor de la trombina presente en la saliva de la sanguijuela. Sin embargo, el resumen no aborda específicamente la hirudina, los agentes derivados de sanguijuela ni la hirudoterapia; la relevancia es, en el mejor de los casos, indirecta, limitada al panorama más amplio de la anticoagulación.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026